| Description |
RLX-33 is a potent, selective and blood-brain barrier (BBB) penetrant relaxin family peptide 3 (RXFP3) antagonist, also blocks relaxin-3-induced ERK1/2 phosphorylation, with IC50 values of 2.36 μM for RXFP3, 7.82 and 13.86 μM for ERK1 and ERK2 phosphorylation, respectively. RLX-33 can block the stimulation of food intake induced by the RXFP3-selective agonist R3/I5 in rats. RLX-33 can be used for the research of metabolic syndrome[1].
|
| Related Catalog |
|
| Target |
IC50: 2.36 μM (RXFP3), 7.82 μM (ERK1 phosphorylation), 13.86 μM (ERK2 phosphorylation)[1]
|
| In Vivo |
RLX-33 (10 mg/kg; IP, single dosage) attenuates the RXFP3-selective agonist R3/I5-induced increase in feeding in male Wistar rats[1]. RLX-33 (10 mg/kg; IP, single dosage) exhibits a good brain penetration and highly protein-bound in rats plasma[1]. Pharmacokinetic Parameters of RLX-33 in male Wistar rats (IP, 10 mg/kg)[1]. plasma brain Cmax (ng/mL) 1401 1552 tmax (h) 0.5 2.0 t1/2 (h) 1.9 4.9 AUCinf (ng/mL·h) 5352 12519 CL_F (mL/min/kg) 43.8 Animal Model: Male Wistar rats (intracerebroventricular administration of R3/I5 stimulated food intake[1] Dosage: 10 mg/kg Administration: IP, single dosage Result: Attenuated the R3/I5-induced increase in food intake. Animal Model: Male Wistar rats[1] Dosage: 10 mg/kg Administration: IP, single dosage (Pharmacokinetic Analysis) Result: Exhibited a good brain penetration and highly protein-bound, with protein binding of 99.8% in rat plasma.
|
| References |
[1]. https://pubmed.ncbi.nlm.nih.gov/35594150/
|
